Terms: = Lymphoma AND HSP90AA1, ENSG00000080824, 3320, P07900, LAP2, HSPN, HSPCAL4, HSPCAL1, HSPCA, HSPC1, HSP90N, HSP90A, Hsp90, Hsp89, HSP86, FLJ31884 AND Prognosis
16 results:
1. A Coumarin-Imidazothiadiazole Derivative, SP11 Abrogates Tumor Growth by Targeting hsp90 and Its Client Proteins.
Nirgude S; Shahana M V ; Ravindran F; Kumar S; Sharma S; Mahadeva R; Mhatre A; Karki SS; Choudhary B
Molecules; 2023 Jul; 28(13):. PubMed ID: 37446888
[TBL] [Abstract] [Full Text] [Related]
2. Heat shock factor 1 is a promising therapeutic target against adult T-cell leukemia.
Ishikawa C; Mori N
Med Oncol; 2023 May; 40(6):172. PubMed ID: 37165174
[TBL] [Abstract] [Full Text] [Related]
3. EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries.
Elshatlawy M; Sampson J; Clarke K; Bayliss R
Mol Oncol; 2023 Jun; 17(6):950-963. PubMed ID: 37149843
[TBL] [Abstract] [Full Text] [Related]
4. The Expression of the RUVBL1 Component of the R2TP Complex Correlates with Poor prognosis in DLBCL.
Lone M; Shadang M; Akhter Q; Kumar M; Mallick S; Gogia A; Nilima N; Chauhan SS; Mir RA
Pathobiology; 2022; 89(3):146-156. PubMed ID: 35078195
[TBL] [Abstract] [Full Text] [Related]
5. hsp90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias.
Mshaik R; Simonet J; Georgievski A; Jamal L; Bechoua S; Ballerini P; Bellaye PS; Mlamla Z; Pais de Barros JP; Geissler A; Francin PJ; Girodon F; Garrido C; Quéré R
Blood Cancer J; 2021 Mar; 11(3):61. PubMed ID: 33737511
[TBL] [Abstract] [Full Text] [Related]
6. Identification and Therapeutic Intervention of Coactivated Anaplastic lymphoma Kinase, Fibroblast Growth Factor Receptor 2, and Ephrin Type-A Receptor 5 Kinases in Hepatocellular Carcinoma.
Wang X; Zhang M; Ping F; Liu H; Sun J; Wang Y; Shen A; Ding J; Geng M
Hepatology; 2019 Feb; 69(2):573-586. PubMed ID: 29356025
[TBL] [Abstract] [Full Text] [Related]
7. Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial.
Weiss L; Melchardt T; Egle A; Hopfinger G; Hackl H; Greil R; Barth J; Rummel M
Ann Hematol; 2017 Jul; 96(7):1155-1162. PubMed ID: 28456850
[TBL] [Abstract] [Full Text] [Related]
8. Emerging treatment for ALK-positive lung cancer.
Sharma J; Pareek V; Liu H; Cheng H
Expert Opin Emerg Drugs; 2016 Jun; 21(2):147-55. PubMed ID: 27122312
[TBL] [Abstract] [Full Text] [Related]
9. A purine scaffold hsp90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-κB.
Gopalakrishnan R; Matta H; Chaudhary PM
Clin Cancer Res; 2013 Sep; 19(18):5016-26. PubMed ID: 23881928
[TBL] [Abstract] [Full Text] [Related]
10. FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy.
Li Z; Graf N; Herrmann K; Jünger A; Aichler M; Feuchtinger A; Baumgart A; Walch A; Peschel C; Schwaiger M; Buck A; Keller U; Dechow T
Cancer Res; 2012 Oct; 72(19):5014-24. PubMed ID: 22875026
[TBL] [Abstract] [Full Text] [Related]
11. miRNA mediated up-regulation of cochaperone p23 acts as an anti-apoptotic factor in childhood acute lymphoblastic leukemia.
Liu X; Zou L; Zhu L; Zhang H; Du C; Li Z; Gao C; Zhao X; Bao S; Zheng H
Leuk Res; 2012 Sep; 36(9):1098-104. PubMed ID: 22677230
[TBL] [Abstract] [Full Text] [Related]
12. JAK-STAT and JAK-PI3K-mTORC1 pathways regulate telomerase transcriptionally and posttranslationally in ATL cells.
Yamada O; Ozaki K; Akiyama M; Kawauchi K
Mol Cancer Ther; 2012 May; 11(5):1112-21. PubMed ID: 22402124
[TBL] [Abstract] [Full Text] [Related]
13. Correlation of seven biological factors (hsp90a, p53, MDM2, Bcl-2, Bax, Cytochrome C, and Cleaved caspase3) with clinical outcomes of ALK+ anaplastic large-cell lymphoma.
Li HL; Huang XP; Zhou XH; Ji TH; Wu ZQ; Wang ZQ; Jiang HY; Liu FR; Zhao T
Biomed Environ Sci; 2011 Dec; 24(6):630-41. PubMed ID: 22365399
[TBL] [Abstract] [Full Text] [Related]
14. Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of hsp90 in mantle cell lymphoma.
Jin L; Tabe Y; Kimura S; Zhou Y; Kuroda J; Asou H; Inaba T; Konopleva M; Andreeff M; Miida T
Br J Cancer; 2011 Jan; 104(1):91-100. PubMed ID: 21139584
[TBL] [Abstract] [Full Text] [Related]
15. The synthetic heat shock protein 90 (hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells.
Tong WG; Estrov Z; Wang Y; O'Brien S; Faderl S; Harris DM; Van Pham Q; Hazan-Halevy I; Liu Z; Koch P; Kantarjian H; Keating MJ; Ferrajoli A
Invest New Drugs; 2011 Dec; 29(6):1206-12. PubMed ID: 20533075
[TBL] [Abstract] [Full Text] [Related]
16. Effect of heat shock protein-90 (hsp90) and vascular endothelial growth factor (VEGF) on survival in acute lymphoblastic leukemia: an immunohistochemical study.
Hacıhanefioglu A; Gonullu E; Mehtap O; Keski H; Yavuz M; Ercin C
Med Oncol; 2011 Sep; 28(3):846-51. PubMed ID: 20422320
[TBL] [Abstract] [Full Text] [Related]
